SSE Ticker: 688177

Bio-Thera Solutions, Ltd.

百奥泰

Authorized Representative: 易贤忠

Board: Star Market

Industry Classification: Biomedicine

Survive the broken arm! In the cold winter, another star drug was forced to terminate the clinical trial enterprise, and how did the capital start again jqknews

Post date May 15, 2022 — 21:44 Post Lock

Breaking Stock

Post date May 2, 2022 — 12:33 Post Lock

Breaking issue of shares, Bio-Otai’s net profit was not enough last year, and it lost 2 billion in IPO and raised 2 billion in the first quarter. Financial Channel Rongyi Information

Post date May 2, 2022 — 12:05 Post Lock

Breaking Stock

Post date May 2, 2022 — 12:05 Post Lock

Breaking Stock

Post date April 29, 2022 — 20:02 Post Lock

Breaking Stock

Post date April 29, 2022 — 19:43 Post Lock

Bio-Tech: Net profit in the first quarter of 2022 is about -110 million yuan per net

Post date April 29, 2022 — 05:56 Post Lock

Bio-Tech: Net profit in 2021 is about 81.94 million yuan per net

Post date April 29, 2022 — 05:55 Post Lock

Bio-Tech: First Realized Profit, Cancellation of Stock Abbreviation Special Logo_Oriental Fortune Net

Post date April 28, 2022 — 22:24 Post Lock

Bio-Tech (688177.SH) received government subsidy of RMB 54.9606 million

Post date April 20, 2022 — 00:21 Post Lock

Bio-Tech (688177.SH): Accumulated government subsidies of 54.9606 million yuan_Individual Stock Information_Market Gold Online

Post date April 19, 2022 — 18:17 Post Lock

Bio-Tech: The company received government subsidies totaling about 54.96 million yuan_ Oriental Fortune Net

Post date April 19, 2022 — 18:09 Post Lock

Bio-Tech: The company received government subsidies totaling about 54.96 million yuan per net

Post date April 19, 2022 — 18:06 Post Lock

Bio-Tech received a government subsidy of RMB 54.9606 million

Post date April 19, 2022 — 17:59 Post Lock

The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG

Post date April 19, 2022 — 09:35 Post Lock

The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG PD-1 Junshi Biotechnology Listed Company_Sina Technology_Sina

Post date April 19, 2022 — 07:36 Post Lock

The competition of innovation and R&D strength of listed pharmaceutical companies shows the dual benefits of business and ESG_Individual Stock Information_Market Gold Online

Post date April 19, 2022 — 07:31 Post Lock

China Biotech's two new coronavirus Omicron inactivated vaccines received clinical approval from Hong Kong Junshi Bio's new crown oral drug VV116 released the latest research results

Post date April 18, 2022 — 18:46 Post Lock

Announcement of Bio-Tech Biopharmaceutical Co., Ltd. on the approval notice for clinical trial of BAT8009 for injection

Post date April 16, 2022 — 08:25 Post Lock

On the evening of April 15th, Shanghai and Shenzhen listed companies announced the latest express of major events_ Oriental Fortune Net

Post date April 15, 2022 — 16:57 Post Lock